Detalles de la búsqueda
1.
Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.
Blood
; 122(20): 3482-91, 2013 Nov 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-24106207
2.
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
Haematologica
; 100(1): 77-86, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25344523
3.
Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.
J Immunol
; 190(1): 231-9, 2013 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23225880
Resultados
1 -
3
de 3
1
Próxima >
>>